Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05929079 · ClinicalTrials.gov registry record · Phase 3

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
1,000
Enrollment target
20
Study locations

NCT05929079 is a Phase 3 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,000 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05929079, a Phase 3 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Conditions Studied

Obesity Type 2 Diabetes Overweight Obstructive Sleep Apnea

Interventions

  • DRUG Placebo
  • DRUG Retatrutide

Study Locations (20)

Florida

  • Excel Medical Clinical Trials - Boca Raton
  • Teradan Clinical Trials, LLC - Brandon
  • Fleming Island Center for Clinical Research - Fleming Island
  • Therafirst Medical Center - Fort Lauderdale
  • Clinical Site Partners LLC, dba Flourish Research - Miami
  • Quantum Clinical Trials - Miami Beach
  • Renstar Medical Research - Ocala
  • Clinical Research Center of Florida - Pompano Beach
  • Palm Beach Research Center - West Palm Beach
  • Clinical Site Partners, LLC dba Flourish Research - Winter Park

California

  • Core Healthcare Group - Cerritos
  • Velocity Clinical Research, Westlake - Los Angeles
  • Valley Clinical Trials, Inc. - Northridge
  • Diablo Clinical Research, Inc. - Walnut Creek

Alabama

  • Pinnacle Research Group, LLC - Anniston
  • Cullman Clinical Trials - Cullman

Georgia

  • NeuroTrials Research Inc - Atlanta
  • Centricity Research Rincon Pulmonology - Rincon

Arkansas

  • Preferred Research Partners - Little Rock

Connecticut

  • Chase Medical Research, LLC - Waterbury

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-07-11
Est. Completion 2026-05
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05929079

The ClinicalTrials.gov registry entry for NCT05929079 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (22% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05929079 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT05929079 about?

NCT05929079 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight". The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study w...

What is the current status of trial NCT05929079?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2023-07-11. Estimated completion is 2026-05.

What conditions does trial NCT05929079 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight, Obstructive Sleep Apnea.

What interventions are being tested in trial NCT05929079?

The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).

Who is sponsoring clinical trial NCT05929079?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05929079 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Type 2 Diabetes

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.